07.09.2024
Therapeutics
$3,189,010.00
36 months
Patient-specific adaptive, electric therapy for Crohn's disease
Despite medical advancements, only 30% of CD patients achieve long-term remission. This limited success is partially due to the inability of current therapies to adapt to the rapidly changing conditions of the disease, leading to side effects and/or suboptimal therapy. Development of a drug-free, electric nerve therapy that can respond to a patient's disease status by administering personalized, effective treatment would represent a new approach to CD therapeutics. The principal investigators (PIs) Drs. Payne and Fallon aim to develop a device that can deliver this therapy, improve outcomes and quality of life for CD patients, and perhaps break through the current therapeutic ceiling.